What the FDA is
The FDA is responsible for the safety, efficacy and security of human and veterinary drugs, biological products and medical devices in the United States. Its Center for Drug Evaluation and Research (CDER) reviews new drugs before they can be sold.
Intended use, not just the label
Under FDA rules, what a product is "intended" for is judged objectively. It can be shown by labelling claims, advertising, written or spoken statements, and the circumstances in which the product is sold.
In 2026 the FDA sent warning letters to several online peptide sellers. The letters said that, despite labels such as "research use only" and "not for human consumption", evidence from the sellers' websites showed the products were intended as drugs for human use. They cited the drug definition in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act and the rule in section 505(a) that a new drug needs an approved application before it is sold.
Some of those letters also pointed to sellers offering bacteriostatic water alongside peptides, which the FDA described as providing the means to prepare an injectable drug for human use.
Compounding and the 503A rules
Compounding is when a pharmacy or doctor prepares a drug for a patient who cannot be treated with an approved medicine. The FDA says compounded drugs are not FDA-approved.
Under section 503A, pharmacies may compound with a bulk substance only if it meets a USP or NF monograph, is part of an approved drug, or appears on the FDA's 503A bulks list. That list is set by regulation (21 CFR 216.23) and currently names six substances.
While the list is being built, the FDA sorts nominated substances into three categories. Category 1 is under evaluation. Category 2 raises significant safety risks. Category 3 was nominated without enough supporting information.
Where peptides have sat
The FDA's safety page lists peptides including BPC-157, TB-500 (the LKKTETQ fragment), AOD-9604, KPV and Semax among substances that were previously in category 2 but whose nominations were withdrawn. For most of them it records concerns about possible immune reactions and limited safety information.
On the FDA's category list updated on 14 May 2026, kisspeptin-10 and ibutamoren mesylate were still in category 2. GHK-Cu, except for injectable routes, was in category 1.
The 2026 advisory committee review
On 23 and 24 July 2026, the FDA's Pharmacy Compounding Advisory Committee discussed BPC-157, KPV, TB-500, MOTs-C, emideltide (DSIP), Semax and Epitalon for possible inclusion on the 503A bulks list.
Advisory committees make non-binding recommendations. The FDA adds substances to the 503A bulks list through notice-and-comment rulemaking. None of this makes a peptide an approved medicine. The position was moving in 2026, so check the FDA's current pages before relying on any of it.
Get advice for your own case
This is general information, not legal advice. For specific products or wording, speak to a regulatory solicitor, or a US regulatory attorney for the US market.
Educational information only. Nothing here is medical advice, dosing guidance or a recommendation to use any substance. Research peptides are not approved medicines and are not for human or animal consumption. Speak to a qualified professional and follow the law where you are.
